D. E. Shaw & Co., Inc. Arvinas, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $156 Billion
- Q3 2025
Call Options
1 transactions
Others Institutions Holding ARVN
# of Institutions
239Shares Held
65.3MCall Options Held
1.23MPut Options Held
372K-
Vanguard Group Inc Valley Forge, PA8.56MShares$90.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$66.2 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA5.58MShares$58.9 Million5.5% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.13MShares$22.5 Million0.01% of portfolio
-
State Street Corp Boston, MA1.87MShares$19.8 Million0.0% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $562M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...